Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer

• Main Authors: Vidhi M. Shah (Author), Craig Dorrell (Author), Adel Al-Fatease (Author), Brittany L. Allen-Petersen (Author), Yeonhee Woo (Author), Yuliya Bortnyak (Author), Rohi Gheewala (Author), Brett C. Sheppard (Author), Rosalie C. Sears (Author), Adam WG. Alani (Author)
• Format: Book
• Published: MDPI AG, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pancreatic ductal adenocarcinoma (PDAC) presents as an unmet clinical challenge for drug delivery due to its unique hypoxic biology. Vinblastine-N-Oxide (CPD100) is a hypoxia-activated prodrug (HAP) that selectively converts to its parent compound, vinblastine, a potent cytotoxic agent, under oxygen...